COMMUNIQUÉS West-GlobeNewswire

Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01/05/2024
Oral Presentation and Four Posters to Highlight Alkeus’ Progress in Advancing Research to Address Unmet Needs for People Affected by Serious Degenerative Eye Diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- [...]
WeightWatchers for Business and Personify Health Partner to Help Employers Address Weight Health Care
01/05/2024
Personify Health clients will now have integrated access to WeightWatchers for Business’s full-spectrum weight health platform NEW YORK and PROVIDENCE, R.I., May 01, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW [...]
SFWJ/MedCana Reacts to US DEA's Rescheduling of Marijuana
01/05/2024
AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN -- SFWJ, doing business as MedCana, a holding company focused in the cannabis and agricultural technology sectors, joins the cannabis industry in acknowledging a [...]
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
01/05/2024
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 [...]
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
01/05/2024
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 01, 2024 ( [...]
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
01/05/2024
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients [...]
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
01/05/2024
The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical [...]
Novo Nordisk A/S - share repurchase programme
01/05/2024
Bagsværd, Denmark, 1 May 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
01/05/2024
MIAMI, FL, May 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
01/05/2024
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker [...]
Cepham’s Luteye Centers on Cellular Senescence to Protect Aging Eyes
01/05/2024
SOMERSET, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- In alignment with Healthy Vision Month in May, Cepham , a leader in Ayurvedic nutraceutical ingredients, announces the launch of Luteye, a branded ingredient that [...]
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
01/05/2024
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“ [...]
Alpha Tau to Participate in May Investor Conferences
01/05/2024
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that [...]
Yield10 Bioscience Announces 1-for-24 Reverse Stock Split
01/05/2024
WOBURN, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that it will effect a 1-for-24 reverse stock split [...]
Bionet America, Inc. Launches New Brio XVet Multiparameter Veterinary Monitors
01/05/2024
Next-generation surgical monitors enhance safety and convenience for veterinary care TUSTIN, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Bionet America, Inc. today announced the launch of the new Brio XVet series, a [...]
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
01/05/2024
Acquire cell therapy manufacturing facility with clinical and commercial capabilities Further ExacTcell platform for additional clinical trials based on successful completion of POC Highlight full year financial results [...]
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
01/05/2024
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first [...]
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
01/05/2024
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership [...]
Goodness Growth Provides CREAM & Fire Updates
01/05/2024
– Josh Rosen to shed Interim title and become Chief Executive Officer; Company provides other key personnel updates – – Company receives a short-term extension of the maturity date on its credit facility – – Company [...]

Pages